Live Breaking News & Updates on செர்ப் ஓடு போஸ்னியன்
Stay updated with breaking news from செர்ப் ஓடு போஸ்னியன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Latest: Italy slowly reopens after pre-holiday closures lmtonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lmtonline.com Daily Mail and Mail on Sunday newspapers.
GENEVA Officials at the World Health Organization pushed back against suggestions that the U.N.-led team investigating the origins of the pandemic in China is not getting enough access or data during its ongoing visit to Wuhan. WHO’s COVID-19 technical lead Maria Van Kerkhove said the team, comprised of experts from 10 countries, has plans to visit the Wuhan Institute of Virology, among other sites. “We need to give them the space to be able to carry out this scientific study,” she said, in response to suggestions that China has been less than transparent about how the outbreak began. WHO’s team arrived in Wuhan last month after a months-long delay to investigate the animal origins of COVID-19. ....
The Latest: US awards $231M contract for at-home virus tests mymotherlode.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mymotherlode.com Daily Mail and Mail on Sunday newspapers.
The Latest: Fauci pushes need for global vaccination effort startribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from startribune.com Daily Mail and Mail on Sunday newspapers.
AMSTERDAM The European Medicines Agency said it has begun an expedited approval process for a combination COVID-19 drug that was granted an emergency use authorization in the U.S. in November. In a statement on Monday, the EU regulator said it has started a “rolling review” of the drug known as REGN-COV2, developed by Regeneron Pharmaceuticals and Roche. It is made of casirivimab and imdevimab, two monoclonal antibodies. The Amsterdam-based EMA said its decision was based on preliminary results from a study that suggests the drug could reduce the amount of virus in the blood, but said “it is too early to draw any conclusions.” It said it was evaluating the first batch of data on the drug, from laboratory and animal studies and that further data from clinical trials would be assessed as they become available. ....